AU3971295A - Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase - Google Patents

Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase

Info

Publication number
AU3971295A
AU3971295A AU39712/95A AU3971295A AU3971295A AU 3971295 A AU3971295 A AU 3971295A AU 39712/95 A AU39712/95 A AU 39712/95A AU 3971295 A AU3971295 A AU 3971295A AU 3971295 A AU3971295 A AU 3971295A
Authority
AU
Australia
Prior art keywords
protein
farnesyl transferase
substituted tetra
pentapeptide inhibitors
pentapeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU39712/95A
Inventor
Gary Louis Bolton
Alfred Campbell
Richard Gowan
John Cooke Hodges
Donald Hupe
Daniele Leonard
Tomi Sawyer
Judith Sebolt-Leopold
Francis J. Tinney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US35347394A priority Critical
Priority to US353473 priority
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Priority to PCT/US1995/014010 priority patent/WO1996017861A1/en
Publication of AU3971295A publication Critical patent/AU3971295A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
AU39712/95A 1994-12-09 1995-10-27 Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase Abandoned AU3971295A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US35347394A true 1994-12-09 1994-12-09
US353473 1994-12-09
PCT/US1995/014010 WO1996017861A1 (en) 1994-12-09 1995-10-27 Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase

Publications (1)

Publication Number Publication Date
AU3971295A true AU3971295A (en) 1996-06-26

Family

ID=23389273

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39712/95A Abandoned AU3971295A (en) 1994-12-09 1995-10-27 Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase

Country Status (5)

Country Link
JP (1) JPH10510261A (en)
AU (1) AU3971295A (en)
CA (1) CA2204144A1 (en)
MX (1) MX9703208A (en)
WO (1) WO1996017861A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
SMP200800063B (en) 2006-04-19 2009-11-06 Novartis Ag benzazolici compounds and benzothiazole -6-0-substituted and inhibition methods of the cfs-1r signal
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
JP5330274B2 (en) 2007-03-01 2013-10-30 ノバルティス アーゲー Pim kinase inhibitors and methods of use thereof
EP2152700B1 (en) 2007-05-21 2013-12-11 Novartis AG Csf-1r inhibitors, compositions, and methods of use
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010144909A1 (en) 2009-06-12 2010-12-16 Novartis Ag Fused heterocyclic compounds and their uses
US8987275B2 (en) 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2624045C2 (en) 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3327125A1 (en) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP3453762A1 (en) 2012-05-02 2019-03-13 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
KR20150088257A (en) 2012-11-28 2015-07-31 머크 샤프 앤드 돔 코포레이션 Compositions and methods for treating cancer
JP6387013B2 (en) 2012-12-20 2018-09-12 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US9266824B2 (en) 2014-01-13 2016-02-23 Warsaw Orthopedic, Inc. Methods and compositions for making an amino acid triisocyanate
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JP2017523215A (en) 2014-08-06 2017-08-17 ノバルティス アーゲー Protein kinase c inhibitors and methods of use thereof
US20180086841A1 (en) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528486A3 (en) * 1991-08-16 1994-04-20 Merck & Co Inc
JPH09504295A (en) * 1993-10-25 1997-04-28 パーク・デイビス・アンド・カンパニー Protein: Farnesyl substituted tetra glycosyltransferases - and pentapeptides inhibitors

Also Published As

Publication number Publication date
WO1996017861A1 (en) 1996-06-13
CA2204144A1 (en) 1996-06-13
JPH10510261A (en) 1998-10-06
MX9703208A (en) 1997-07-31

Similar Documents

Publication Publication Date Title
AU698911B2 (en) Thrombin inhibitors
AU637497B2 (en) Methods and compositions for the identification, characterization and inhibition of farnesyl protein transferase
AU687449B2 (en) Inhibitors of beta-amyloid protein production
AU678625B2 (en) Inhibitors of farnesyl-protein transferase
AU1072897A (en) Peptide binding the klvff-sequence of amyloid beta
AU5432896A (en) Tricyclic compounds useful for inhibition of farnesyl protei n transferase
AU7481994A (en) Therapeutic peptide derivatives
AU691820B2 (en) Prodrugs of protein tyrosine kinase inhibitors
AU1087497A (en) Clamp assembly and method of use
AU5695998A (en) Artificial vascular valves
AU2913197A (en) Surgical sealing sleeve
AU7012896A (en) Vegf-related protein
AU6899996A (en) Stabilizer for human joints
IL122814D0 (en) Inhibitors of platelet aggregation
AU2891795A (en) Enzyme inhibitors
AU5534896A (en) Thrombin inhibitors
AU5721798A (en) Human mage-like protein
AU6292896A (en) Inhibition of vascular occlusion following vascular intervention
HU9602516D0 (en) Isoprenyl transferase inhibitors
AU3698295A (en) Amino purine-beta -d-ribofuranuronamide derivatives
ZA9605868B (en) Farnesyl transferase inhibitors their preparation and pharmaceutical compositions comprising them
AU692241B2 (en) Inhibitors of farnesyl-protein transferase
AU2293995A (en) Stop-cock valve
AU2747497A (en) Compositions and methods for antisense inhibition of protein translation
AU7041294A (en) Inhibitors of farnesyl-protein transferase